Dr. Paul Walker reports

SPECTRAL ANNOUNCES FIRST ORDERS OF ITS PROPRIETARY CRRT MACHINE

Following the execution of the previously announced distribution agreement for Spectral Medical Inc.'s proprietary continuous renal replacement therapy (CRRT) machine with a private United States company, Spectral is now ready to ship out the first order of machines and related disposable for a cumulative revenue of $120,000. A second order in excess of $450,000 has been processed and will be ready for shipment in the second quarter.

"The Spectral CRRT machine was developed to be user friendly and flexible in performing continuous renal replacement therapy in a variety of modalities. We are working closely with our early adopters to ensure its successful launch," said Dr. Gualtiero Guadagni, vice-president of sales and marketing at Spectral.

About Spectral's CRRT machine

The Spectral CRRT machine (previously known as the SAM Pump) is an innovative instrument based on a patented cassette technology that can be used for CRRT and therapeutic plasma exchange (TPE) modalities. This CRRT machine is user friendly, built on a small footprint, and allows for use of any dialyzer and/or dialysis membrane available on the market. The company has exclusive licence rights for the CRRT machine in North America for all hospital applications and has worldwide exclusivity for hemoperfusion application.

About Spectral Medical Inc.

Spectral Medical is a phase 3 company seeking United States Food and Drug Administration approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the company's endotoxin activity assay, the only FDA-cleared diagnostic for the risk of developing sepsis.

We seek Safe Harbor.